Reviva Pharmaceuticals is excited to announce that it has been selected
as a Winner for the prestigious 2014 TiE50 Awards at the organization's
annual entrepreneurial conference, TiEcon in Santa Clara, California on
May 16, 2014. Returning for the sixth year in a row, this year's TiE50
was open to all technology companies worldwide.
"It is an honor and privilege to receive the TiE50 Award for 2014.
We at Reviva Pharmaceuticals are proud that our commitment for
developing new therapies to the treatment of patients with major unmet
medical needs has been recognized through this award" - Laxminarayan
Bhat, PhD, Founder and CEO, Reviva Pharmaceuticals, Inc.
"In the six short years since inception, the TiE 50 program has become a
global brand that attracts thousands of companies worldwide for this
recognition," said Venktesh Shukla, president of TiE, Silicon Valley.
"It is unique in terms of rigor of selection and the broad scope of
companies that it reviews for this award and is one of TiE Silicon
Valley's most successful programs. It is also worth mentioning that this
is the only awards recognition in technology to be held by a large
global non-profit organization."
To determine the winner, a panel of experts will screen the companies
and create a list of the "2014 TiE50 Top Startups." This list
will then be reviewed further by a screening committee of deep domain
experts. About 100 of the best of the breed companies are selected to
the elite TiE50 Finalit pool. Finally, this pool of TiE50
Finalists are judged by a panel of highly accomplished team made up
of serial entrepreneurs, venture capitalists, angel investors, CEOs and
well-rounded technology experts, to determine finalists and winners.
Companies will be evaluated on three parameters: Business Model, IP
Value and Leadership team.
At TiEcon 2014, 20 of the top startups from each of the five segments
will be chosen to pitch their ideas, and winners will be announced on
stage that evening.
This year at the event, attendees and TiE50 participants will also have
the chance to hear from three previous TiE50 winners who have made
successful exits recently: FireEye, Pearl Therapeutics and Rubicon
"This year the TiE50 Awards Program screened more than 2800 companies
from 27 countries. The finalist pool is represented by early through
late stage companies. A star attraction of the conference is TiE50
Finalist presentations. Audiences are treated to great ideas and amazing
technologies" said Ram K. Reddy, the program chair.
The TiE50 track record since its inception in May 2009 shows that 94% of
the winners and finalists have been funded, attracting Billions in
investments. Many of these companies have been acquired, merged or gone
public. For further details on the TiE50, visit www.tie50.org.
About Reviva Pharmaceuticals, Inc.
Reviva is a privately-held, angel financed, fast growing, late-stage
clinical development company located in San Jose, California. The
company is focused on the discovery, development and commercialization
of new, safe and highly effective novel, next generation therapeutic
drugs using an integrated chemical genomics approach and proprietary
chemistries. Reviva is developing Best-in-Class new drugs for central
nervous system (CNS), metabolic, cardiovascular (CV), inflammation and
pain indications. Its lead product RP5063, a broad spectrum
antipsychotic drug is currently in Phase 3 development for schizophrenia.
Reviva's leadership team has a strong background and a track record in
successful and rapid product development, regulatory approval and
commercialization. Founded in 2006, Reviva has been financed by angel
investors comprised of medical doctors, successful entrepreneurs, and
professionals in the healthcare and high-tech industries.
For additional information, please visit our website at www.revivapharma.com.
[ Back To NFVZone's Homepage ]